Table 1 |.
Expression of TAM receptors and ligands and their functional relevance in cancer
| Cancer type | AXL | MERTK | TYRO3 | GAS6 | PROS1 |
|---|---|---|---|---|---|
| Haematological cancer | |||||
| AML | Yes (E, B, F) | Yes (E, F) | Yes (E) | Yes (E, B) | Yes (E) |
| Chronic myeloid leukaemia | Yes (E, F) | Yes (E) | |||
| B-CLL | Yes (E) | ||||
| Acute lymphoblastic leukaemia | Yes (E, F) | Yes (E, F) | |||
| Mantle cell | Yes (E) | ||||
| Multiple myeloma | Yes (E) | Yes (E) | Yes (E) | ||
| Solid tumour | |||||
| Breast | Yes (E, B, F) | Yes (F) | Yes (E, F) | ||
| Head and neck | Yes (B) | ||||
| Colorectal | Yes (E, B, F) | Yes (F) | Yes (E) | ||
| Pancreatic | Yes (E, B, F) | Yes (F) | Yes (F) | Yes (E) | |
| Oesophageal | Yes (E, B, F) | ||||
| Gastric | Yes (E, B, F) | Yes (B) | Yes (E, F) | ||
| Melanoma | Yes (E, F) | Yes (E, F) | Yes (F) | Yes (F) | |
| Hepatocellular | Yes (F) | ||||
| Squamous cell | Yes (E, F) | ||||
| NSCLC | Yes (E, B, F) | Yes (E, F) | Yes (E) | Yes (B) | Yes (E) |
| Ovarian | Yes (E, B, F) | Yes (E) | |||
| Cervical | Yes (F) | ||||
| Endometrial | Yes (E) | Yes (E) | Yes (E) | ||
| Prostate | Yes (E, F) | Yes (E) | Yes (E) | Yes (F) | Yes (E, B, F) |
| Thyroid | Yes (E, F) | Yes (E, F) | Yes (E, F) | Yes (E) | |
| Bladder | Yes (E, B, F) | ||||
| Renal | Yes (E, F) | Yes (E, B, F) | |||
| Mesothelioma | Yes (E, F) | ||||
| Oral squamous | Yes (B) | ||||
| Glioblastoma | Yes (E, B, F) | Yes (E, F) | Yes (E, B) | Yes (E) | |
| Neuroblastoma | Yes (F) | ||||
| Schwannoma | Yes (E, F) | Yes (E) | Yes (E) | Yes (E, F) | |
| Kaposi’s sarcoma | Yes (E, F) | ||||
| Osteosarcoma | Yes (E, B) | Yes (F) | |||
| Rhadomyosarcoma | Yes (E) | ||||
AML, acute myeloid leukaemia; B, validated as a prognostic biomarker; B-CLL, B cell chronic lymphocytic leukaemia; E, elevated expression in tumours; F, positive correlation between expression and functional relevance; GAS6, growth arrest-specific protein 6; NSCLC, non-small-cell lung cancer; PROS1, vitamin K-dependent protein S1.